Statements (40)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Sandoz's generic business in the US
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:ceo |
gptkb:N._Govindarajan
|
| gptkbp:employees |
Over 20,000
|
| gptkbp:founded |
gptkb:1986
|
| gptkbp:founder |
gptkb:K._Nityananda_Reddy
|
| gptkbp:headquarters |
gptkb:Hyderabad,_India
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aurobindo Pharma
|
| gptkbp:market |
Global
|
| gptkbp:partnerships |
Various global pharmaceutical companies
|
| gptkbp:production_location |
Facilities in the US
Multiple facilities in India |
| gptkbp:products |
Active pharmaceutical ingredients (APIs)
Generic pharmaceuticals |
| gptkbp:regulatory_compliance |
FDA approved
EMA approved WHO approved |
| gptkbp:research_and_development |
Strong focus on R& D
|
| gptkbp:research_areas |
gptkb:diabetes
gptkb:Oncology Central nervous system Gastroenterology Pain management Antibiotics Dermatology Cardiovascular Respiratory Antiretrovirals |
| gptkbp:revenue |
$1.5 billion (2021)
|
| gptkbp:social_responsibility |
Education programs
Community health initiatives Environmental sustainability efforts Employee welfare programs |
| gptkbp:stock_exchange |
gptkb:BSE
NSE |
| gptkbp:subsidiaries |
gptkb:Aurobindo_Pharma_USA,_Inc.
|
| gptkbp:website |
www.aurobindo.com
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:bfsLayer |
4
|